Twist Bioscience enters the week after earnings with a striking internal contradiction: executives are selling aggressively into a stock that has rallied more than 290% year-to-date, while short sellers are quietly rebuilding positions and options traders are turning more defensive.
The insider selling is the standout angle here. CEO and founder Emily Leproust sold more than 133,000 shares across two transactions on August 10 and 12, generating over $16.6 million in proceeds at prices between $125 and $126. That followed a wave of selling on August 3 — earnings day — when the President/COO, Chief Legal Officer, Chief Accounting Officer, and a Senior Vice President all trimmed holdings at around $85. The net insider position over the past 90 days is technically positive, driven by prior grants rather than purchases, but the pattern is almost entirely one-directional: insiders are selling into strength at every price level from $85 to $125. That is worth watching against a backdrop where the stock has already pulled back to $116.10, shedding nearly 6% on the week and 6.7% in Tuesday's session alone.
The positioning picture reinforces the caution. Short interest has climbed to just under 24% of the free float — elevated territory — and has been creeping higher all month, adding roughly 3% over the past week and 5.6% over the past month. Despite that level of short exposure, the borrow market is notably uncongested. Availability is running at roughly 293%, meaning there are nearly three shares available to lend for every share already borrowed. Cost to borrow is a modest 0.47%, barely above its 30-day average. Shorts face no mechanical squeeze pressure at current availability levels. On the options side, the put/call ratio has drifted to 0.49 — about 1.7 standard deviations above its 20-day average of 0.36 — a shift toward more defensive positioning that has built steadily since early August, when the ratio was sitting below 0.30.
The Street is broadly bullish but now having to catch up to a stock that has already run hard. After earnings on August 3, Piper Sandler raised its target from $85 to $115, maintaining Overweight. Baird nudged its target to $115 from $113, also holding Outperform. Both moves look calibrated to a stock that has since touched $125. Canaccord — which initiated in June with a Buy and a $90 target — subsequently lifted to $120. The consensus mean price target is $105.30, which is now below the current price, suggesting the Street's collective pencil hasn't yet caught up to recent gains. That overhang is consistent with the bear case, which flags margin risk and heavy dependence on Americas revenue. The bull case centers on the AI drug-discovery tailwind lifting Twist's NGS segment, with operating leverage from expanding manufacturing capacity. The EPS surprise factor score ranks at the 95th percentile of the universe — the company has been a consistent beater — but the short score of 69.6 (and climbing) flags that the bearish flow is gaining weight even as fundamentals improve.
Institutional ownership adds a layer of complexity. ARK Investment Management holds 10.1% of shares — the largest single position — and showed no change in its last reported holdings through July 31. Fidelity (FMR LLC) added nearly 2.8 million shares in the same period, a substantial addition. Invesco added 849,000 shares. Those inflows helped absorb earlier selling pressure, but they also mean a handful of large active managers are now sitting on significant gains as insiders reduce. Farallon Capital, which added 1.42 million shares as recently as March, is also a notable presence.
The August 3 earnings print delivered a 8.6% one-day gain and a remarkable 36% five-day move. The next event is scheduled for November 13. Between now and then, the key dynamic to watch is whether analyst price target upgrades can close the gap to where the stock is trading, or whether the combination of insider-driven selling pressure, rising short interest, and a put/call ratio at multi-month highs begins to weigh more meaningfully on the price.
See the live data behind this article on ORTEX.
Open TWST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
